



**ASX RELEASE**

15 June 2011

## **QRxPharma CEO discusses Comparative Safety Study on Boardroom Radio**

**Sydney, Australia and Bedminster, New Jersey --** QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) provides the opportunity to listen to an audio broadcast with Dr. John Holaday, Managing Director and Chief Executive Officer of QRxPharma discussing the findings of its comparative safety study (Study 022), following our study results announcement on 14 June 2011.

*To listen*, copy the following details into your web browser: **[brr.com.au/event/81716](http://brr.com.au/event/81716)**, with the audio broadcast available on Boardroom Radio from 12.30pm AEST - 15 June 2011.

###


For more information please contact:

John W Holaday, Ph.D.  
Managing Director and Chief Executive Officer  
Tel: +1 301 908 3086  
Email: [john.holaday@qrxpharma.com](mailto:john.holaday@qrxpharma.com)

Chris J Campbell  
Chief Financial Officer and Company Secretary  
Tel: +61 2 9492 8021  
Email: [chris.campbell@qrxpharma.com](mailto:chris.campbell@qrxpharma.com)

### **About QRxPharma**

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to co-promote its products in the US and seeks strategic partnerships for worldwide markets. QRxPharma's lead product candidate, immediate release MoxDuo, has successfully completed pivotal Phase 3 studies and the Company expects to file its New Drug Application (NDA) with the US Food and Drug Administration (FDA) in mid-2011. The Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo, as well as other



technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit [www.qrxpharma.com](http://www.qrxpharma.com).

### **Forward Looking Statements**

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward- looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.